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Abstract 
Aim: The object of the study was to evaluate the long term efficacy and safety of ropivacaine 0,5% vs tetracaine 0,5% for topical 
anesthesia in intravitreal injection  
of dexamethasone in patients with diabetic macular edema (DME) and anti-vascular endothelial growth factor (VEGF) therapy.  
Methods: Thirty-seven patients were enrolled in the study. Intravitreal anti-vascular endothelial growth factor (VEGF) and 
Dexamethasone were placed in DME patients.  
Intravitreal administration determines appropriate and long-lasting drug's concentration without systemic side effects. Topical 
anesthesia under ropivacaine 0,5% vs tetracaine 0,5% was performed. 
Results: Intravitreal injection without any supplemental anesthesia and sedation was realized. Patients reported mild pain 
(recorded by a 0 to 10 scale)  during the procedure with optimal operative result. 
Conclusions: Topical anesthesia with ropivacaine and tetracaine is safe and effective in intravitreal injection. The long-lasting 
anesthesia secured low pain during this limited but unpleasant procedure. 
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Introduction  
Intravitreal drugs administration determines 
appropriate and long-lasting pharmacological 
concentration with reduced systemic side effects [1]. 
Intravitreal injection obtain effective drug's concentration 
in limited time [1,2]. Frequently, intravitreal procedures 
are considered for retinopathy treatment of age related 
Macular Degeneration, wet variant (ARMD) [3],  in 
Diabetic Proliferant and in related Macular Edema [4], in 
uveitis [5-8],  in retinal occlusion [1], in high myopia[9]. 
In these pathologies, therapeutic protocols refer to drugs 
with different pharmaceutical characteristics, at rates 
ranging from 4 to 6 weeks for 1-2 years, injected in the 
bulbar space. This strategy prevent angiogenesis, reduce 
retinal edema, improves the best visual acuity (BVA)[10].  
The injection technique requires antiseptic maneuvers in 
the operating room and local anesthetics utilization [11]. 
The procedures of topical anesthesia consist in: 
instillation of eye drops or gel, placing of a cotton swab 
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soaked in anesthetic below the upper eyelid, 
subconjunctival injection of lidocaine solutions or 
peribulbar block [12-14].  
In the meantime, to secure more comfortable procedures, 
new and  more effective topical anesthetic agents were 
tested in ocular surgery [15], in particular in 
phacoemulsification procedures for cataract surgery: 
Oxibuprocaina, Bupivacaine, Lidocaine 1%, Ropivacaine 
0,5 % and 1%   [16-20]. 
    At present there are no studies that emphasize the 
methods of administration and the best local anesthetic 
agents for patient's analgesia [21], nor standardized 
anesthesia's protocols of intravitreal injections for the 
control of patient's discomfort [22]. The subconjunctival 
and peribulbar anesthesia, while causing better analgesia, 
also involving the iris and ciliary body, compared with 
the drop's instillation, often result to be painful and less 
tolerated [23]. Thus, the purpose of the present study was 
to evaluate the efficacy and safety of Ropivacaine 0,5% 
solutions vs Tetracaine 0.5 % eyedrops and cotton swab 
soaked with cocaine 4% in patients receiving intravitreal 
therapy.  
Ropivacaine is a long-lasting anesthetic agent with 
reduced systemic effects; we evaluated the efficacy of 
ropivacaine for topical anesthesia in intravitreal injection.  
 
Materials  and Methods 
 
Patients 
    In this clinical  randomized trial 48 patients, from 
March  2015 to November 2015, divided in two groups 
each, 24 to A group and 24 to B group, respectively 
medicated with Ropivacaine 0,5% solution and 
Tetracaine 0.5% eyedrops with cocaine 4% cotton swab. 
Demographic data of the patients  are reported in Table 
1. 
 
Table 1. Demographic of subjects included in the study. 
Demographic and clinical features 
Age 66.34 ± 9.35
Gender 32M/16F
 
Data are expressed as mean±standard deviation M: male; F: female 
 
This study received the approval of the Institutional 
Review Board of  the Sapienza University of Rome and 
was in agreement with the Helsinki Declaration.All 
patients received full informations and a written 
informed consent was obtained from each patient.  
 
Treatment 
    All injections were performed under sterile conditions, 
after Ropivacaine 0,5% solution (Naropine®, 
AstraZeneca, UK) to patients of A group and Tetracaine 
0.5% eyedrops in group B, one drop every 5 minutes for 
five times were administered, before positioning of 
blepharostat and surgery [24]. 
No preoperative or intraoperative sedative was 
administered. All operations were performed by two 
surgeons with the same standardized technique. 
 
Inclusion criteria 
    Inclusion criteria were: age  18 and patients requiring 
intravitreal injection therapy. 
Exclusion criteria were previous allergic reaction to local 
anesthetics, psychiatric diseases, pregnancy, anxiety, 
deafness, and languages barriers. Our patients had a 
complete ophthalmologic examination before the surgery, 
including in particular best-corrected visual acuity and 
slit-lamp biomicroscopy of the anterior segment. 
 
Evaluations  
    At the end of the procedure, patients were asked to 
answer about the pain experienced during the 
administration of the Ropivacaine 0,5% solution in 
group A patients and Tetracaine 0.5%  eyedrops in B 
group patients, during the intravitreal injection, and the 
immediate postoperative period.  
The pain level perceived by the patients was classified 
with two scales: the VAS (visual analogue scale) pain 
score from 0 (no pain) to 10 (the worst pain) according 
to Functional Oksuz et al [25], and the WB (Wong- 
Baker) FACES pain score [26, 27]. 
 
    The latter one was evaluated by the assistant surgeon, 
based on the expression of the patient's face during 
injection (Fig. 1). Such scales have already been used in 
ophthalmic trials of pain [28] and analgesia [29]. 
 
 
  
 
 
 
Fig. 1  VAS (Visual Analogue Scale) for pain  (above) e WB 
(Wong-Baker) FACES pain rating scale (under),  for intravitreal 
pain test. 
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Efficacy criteria 
    Primary outcome included the efficacy of Ropivacaine 
0,5%  solution versus  Tetracaine 0.5%  eyedrops with 
cocaine 4% cotton swab,  for topical anesthesia in 
intravitreal injection. Secondary outcome considered the 
safety and tolerance of the anesthetic agents during the 
procedure.  
 
 
Statistical analysis  
    We used the Student's t test to evaluate the result's 
statistical significance in the two groups. The Tables 2 
highlights the average value of each group with respect to 
both scales, while Table 3 evidences the result of Student 
T test, setting the VAS pain score to p = 0.80 and WB 
faces pain score to p = 0:56. The differences between the 
scores are not statistically significant, thus the  analgesic 
effect of two anesthetic agents can be considered 
analogue. 
 
 
 Table. 2 Visual Analog Scale (VAS) and Wong - Baker Faces Score 
(WB FACES pain score) average value 
 
 
Table. 3  Student T test (p<0,05)  
GROUPS VAS WB 
Group 1 22.24±4.01 3.12±1.80
Group 2  21.12±4.76 2.92±1.60
P value 0.80 0.56 
 
 
 
Results  
 
    The average procedure time was 11 minutes. During 
intravitreal injection, the average pain score was  22.24  ± 
4.01 in group A  e 21.12 ±  4.76  in  group B. None local 
or systemic adverse events resulted from the topical 
Ropivacaine and Tetracaine administration; all the 
procedures were fulfilled without any supplemental 
anesthesia or sedative drugs administration. 
Complications 
 
    One patient suffered for a subconjunctival hemorrage, 
dependent on intravitreal injection, spontaneously 
receded after ten days. 
None of the patients evidenced ophthalmic or systemic 
noteworthy side effect in the immediate postoperative 
period. 
The control visit  after seven days excluded corneal 
endothelium damages or any other problem depending 
on local anesthetics administration. 
 
Discussion 
 
    The intravitreal injection procedures represent the 
reference therapeutic methodology for the management 
of retinal pathologies2. Subconjunctival infiltration of 
anesthetic agents and peribulbar block can be an 
unpleasant experience for patients scheduled for 
intravitreal procedure. Our interest was to make the 
intravitreal treatment more comfortable for those patients 
who are opposed to the procedure under topical 
anesthesia [28]. 
We tested the effectiveness of  Ropivacaine 0,50% 
solution versus  Tetracaine 0.5% eyedrops with cocaine 
4% cotton swab, for topical anesthesia. These anesthetics 
agents proved adequate analgesia for cataract surgery and 
high safety level with limited systemic adverse events. 
[16,18,20]. 
    The literature is unanimous in recognizing the lack of 
standardized guidelines about the reference anesthetic 
technique for intravitreal  injection. The subconjunctival 
local anesthetics and peribulbar block   are both painful 
and often not well tolerated by the patient [11, 12,14, 
20] 
    Cintra [22] compares topical anesthesia with 
subconjunctival infiltration and peribulbar block, 
evidencing similar results between subconjunctival and 
topical tecnique. Peribulbar block is higher but definitely 
more invasive and painful of eyedrops. Kaderli et al [12]  
compared topical anesthesia with subconjunctival 
lidocaine 4% ; the latter obtained greater analgesia, 
resulting more painful and associated with increased risk 
of subconjunctival hemorrhage. 
    Kozak et al [12] and Friedman et al. [14]  confirmed 
that  topical anesthesia with 2% lidocaine gel and the 
subconjunctival infiltration are likewise analgesics. A 
randomized trial, comparing the analgesic efficacy of 
Proparacaine, Tetracaine, Lidocaine swab and 
subconjunctival injection of Lidocaine, excluded 
significant differences [23]. A further study compared the 
effectiveness of Levobupivacaine vs Bupivacaine in 
peribulbar anesthesia  observed that Levobupivacaine is 
safe and useful even in elderly patients compared to 
general anesthesia [20]. 
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    We employed low dosage Ropivacaine 0.5% to limit 
corneal toxicity; only 0.01% ropivacaine in vitro was 
considered non-toxic, in the absence of anesthetic effect 
[30]. Our choice was free of any corneal damage after 
seven days. 
The results emerging from our study did not show a 
statistically significant difference in pain perception in 
both groups of patients considered. The pain level, 
evaluated both with VAS score or with the assistant one's 
(WB faces pain score), it is similar with both anesthetic 
agents. 
Anyway, topical anesthesia was less invasive and side 
effects free of subconjunctival and peribulbar tecniques. 
The pain resulting from the puncture, the risk of 
chemosis and subconjunctival hemorrhage, together with 
higher skills needed and, not least, higher costs, limited 
the loco-regional tecniques to patients with subjective 
problems. 
 
    The inability to avoid eye's movement, the low pain 
threshold and the anxiety condition are the major 
controindication to topical anesthesia for intravitreal 
procedures. 
Therefore, the outcomes were maintained: topical 
anesthesia with Ropivacaine, and Tetracaine were 
effective because they provided adequate analgesia, or 
mild pain; the anesthetic tecnique was minimally invasive 
and no apparent toxicity or systemic side effects occurred. 
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